Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Up 58.7% in May

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant increase in short interest in May. As of May 29th, there was short interest totaling 4,598 shares, an increase of 58.7% from the May 14th total of 2,897 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 21,087 shares, the short-interest ratio is currently 0.2 days.

Bone Biologics Trading Down 4.4%

NASDAQ BBLG traded down $0.06 on Tuesday, reaching $1.38. 33,792 shares of the company were exchanged, compared to its average volume of 21,108. The business’s fifty day moving average price is $1.29 and its 200 day moving average price is $1.42. The stock has a market capitalization of $2.48 million, a P/E ratio of -0.62 and a beta of 0.93. Bone Biologics has a fifty-two week low of $1.05 and a fifty-two week high of $6.75.

Bone Biologics (NASDAQ:BBLG) last issued its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.43). Equities research analysts forecast that Bone Biologics will post -1.52 earnings per share for the current year.

Institutional Investors Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC boosted its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.